Correll CK, et al. - In this retrospective, observational case series study, researchers reported the clinical characteristics of childhood-onset lupus erythematosus panniculitis (LEP), a rare and chronic disfiguring disease, and described on the use of rituximab in treatment-refractory childhood-onset LEP. Between July 1, 2014, and July 1, 2018, four patients with childhood-onset LEP who presented to a single-center, tertiary care clinic with pediatric dermatology and pediatric rheumatology clinics and were treated with rituximab were included. According to results, improvement had been reported during rituximab therapy. Data reported that all patients were given a quick and sustained response to rituximab therapy. The results obtained from this case series indicate that rituximab can be an effective and well-tolerated treatment.